SynthesisJournal of translational medicine2025
Meta-analysis of comparing CAR-T and bispecific antibody therapy in relapsed/refractory indolent B-cell non-Hodgkin's lymphomas.
Synthesis in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Immune Signature Features, Including TLR2 and TLR4 Expression, Are Associated with Complete Remission After CD19 CAR-T Cell Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndolent B-cell non-Hodgkin’s lymphomas (B-NHLs), including follicular lymphoma (FL) and marginal zone lymphoma (MZL), typically demonstrate slow progression but frequently follow a relapsing-remitting course with conventional therapies. Chimeric antigen receptor T-cell (CAR-T) and bi-specific antibodies (BsAbs) therapies have revolutionized treatment for relapsed/refractory (R/R) B-NHLs. However comparative data on the efficacy of CAR-T therapy versus BsAbs in indolent B-NHLs remain limited. This meta-analysis systematically evaluated the efficacy and safety profiles of these two innovative treatments in patients with R/R FL and MZL.
methodsWe conducted a comprehensive search of MEDLINE, Embase, Cochrane Central Register of Controlled Trial databases, and international conference abstracts (through June 30, 2025) for studies investigating CAR-T or BsAb therapies in R/R FL and MZL. Primary outcome was pooled complete response (CR) rate. Other outcomes included 2-year progression-free survival (PFS), 2-year overall survival (OS), non-relapse mortality (NRM), and adverse events (AEs). Meta-regression analyses were performed to adjust for relevant clinical covariates.
resultsOur analysis included 19 publications (n = 1,760 patients), comprising 10 CAR-T and 9 BsAbs studies. The single-arm meta-analysis showed that CAR-T therapy demonstrated superior efficacy, with higher pooled CR rate (80.73% vs. 67.14%; p = 0.0003), 2-year PFS (68.84% vs. 47.71%; p = 0.0006), and 2-year OS (88.37% vs. 75.26%; p = 0.049) compared to BsAbs. NRM per 100 person-years was similar between two modalities (3.89 vs 3.86, p = 0.9871). CAR-T benefits persisted in third-line or later settings, as well as in analyses restricted to clinical trial data. Multivariate meta-regression confirmed CAR-T’s superiority for CR independent of median age. Safety analysis revealed CAR-T group had higher incidence of grade ≥3 neurotoxicity (7.48% vs. 0.23%, p = 0.0029), neutropenia (58.90% vs. 26.21%; p = 0007), thrombocytopenia (16.77% vs. 5.00%; p = 0.005), but lower incidence of grade ≥3 infection per 100 person-months (0.38 vs. 0.91, p = 0.040) than BsAb group. No differences were observed in grade ≥3 cytokine release syndrome or anemia.
conclusionCAR-T therapy offered superior efficacy and survival in R/R indolent B-NHLs compared to BsAbs, albeit with increased AEs, highlighting the need for careful patient selection and toxicity management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.